MA47671B1 - Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf - Google Patents

Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf

Info

Publication number
MA47671B1
MA47671B1 MA47671A MA47671A MA47671B1 MA 47671 B1 MA47671 B1 MA 47671B1 MA 47671 A MA47671 A MA 47671A MA 47671 A MA47671 A MA 47671A MA 47671 B1 MA47671 B1 MA 47671B1
Authority
MA
Morocco
Prior art keywords
ligand
trimer
antigen binding
binding molecules
tnf family
Prior art date
Application number
MA47671A
Other languages
English (en)
Other versions
MA47671A (fr
Inventor
Ekkehard Moessner
Christian Klein
Peter Bruenker
Koller Claudia Ferrara
Sandra Grau-Richards
Joerg Thomas Regula
Pablo Umaña
Maria Amann
Christina Claus
Viktor Levitski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA47671A publication Critical patent/MA47671A/fr
Publication of MA47671B1 publication Critical patent/MA47671B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouvelles molécules de liaison d'antigène contenant un trimère de ligand de la famille tnf comprenant (a) au moins un fragment capable de se lier spécifiquement à cd19 et (b) un premier et un second polypeptide qui sont liés l'un à l'autre par une liaison disulfure, caractérisés en ce que le premier polypeptide comprend deux ectodomaines d'un membre de la famille des ligands du tnf ou des fragments de ceux-ci qui sont reliés entre eux par un lieur peptidique et en ce que le second polypeptide comprend un seul ectodomaine dudit membre de la famille des ligands du tnf ou un fragment de celui-ci, dans lequel le le membre de la famille des ligands du tnf est le 4-1bbl.
MA47671A 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf MA47671B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193260 2014-11-14
EP15183736 2015-09-03
EP15188142 2015-10-02

Publications (2)

Publication Number Publication Date
MA47671A MA47671A (fr) 2019-05-29
MA47671B1 true MA47671B1 (fr) 2021-05-31

Family

ID=51897184

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47671A MA47671B1 (fr) 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf

Country Status (2)

Country Link
AR (1) AR102623A1 (fr)
MA (1) MA47671B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230187087A1 (en) * 2020-06-03 2023-06-15 Koninklijke Philips N.V. Radiology operations command center (rocc) local technologist - supertechnologist matching
CN120304822B (zh) * 2025-06-17 2025-08-15 重庆联芯致康生物科技有限公司 一种蛋白质监测装置及其应用

Also Published As

Publication number Publication date
AR102623A1 (es) 2017-03-15
MA47671A (fr) 2019-05-29

Similar Documents

Publication Publication Date Title
MA40882A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
PH12018502367A1 (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
PH12019500270A1 (en) Combination therapy for cancer
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2021013783A (es) Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus.
WO2016054598A3 (fr) Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2014194274A3 (fr) Protéines de liaison à l'antigène du récepteur de l'oncostatine m
WO2016016651A3 (fr) Traitement et prévention du paludisme
MA47671A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
FR3001729B1 (fr) Mutants du facteur x
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
FR3018357B1 (fr) Nouvelles lectines et applications pour la detection de marqueurs d'etats pathologiques
EA201991139A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением
MA50374B1 (fr) Compositions d'anticorps pour le traitement de tumeurs
TH1801002025A (th) โปรตีนซึ่งจับแอนติเจนต้าน-tigit และวิธีการใช้โปรตีนนั้น